Abstract
Importance Apolipoprotein B (apoB), low-density lipoprotein cholesterol (LDL-C), and possibly triglycerides (TG) play causal roles in the aetiology of coronary artery disease (CAD). However, trial evidence for effects of intensive LDL-C lowering and TG lowering on mortality is less definitive.
Objectives To investigate dose-response relations of apoB, LDL-C, and TG with CAD and mortality overall, by sex, and by age.
Design We performed linear Mendelian randomization (MR) analyses to assess the associations of genetically-predicted apoB, LDL-C, and TG with CAD, all-cause mortality, and cause-specific mortality. We also performed non-linear MR analyses, dividing the population into 10 strata, to assess stratum-specific estimates and characterise the shape of these associations.
Setting UK Biobank.
Participants 347,797 European ancestry participants (23,818 CAD cases and 23,848 deaths).
Exposures Genetically-predicted apoB, LDL-C, and TG.
Main outcomes and measures CAD, all-cause mortality, cardiovascular mortality, cancer mortality, and non-cardiovascular/cancer mortality.
Results Genetically-predicted apoB was positively associated with CAD (odds ratio (OR) 1.65 per standard deviation increase [95% confidence interval 1.57, 1.73]), all-cause mortality (hazard ratio (HR) 1.11 [1.06, 1.16]), and cardiovascular mortality (HR 1.36 [1.24, 1.50]), with some evidence for stronger associations in men than women. Findings were similar for LDL-C. Genetically-predicted TG was positively associated with CAD (OR 1.60 [1.52, 1.69]), all-cause mortality (HR 1.08 [1.03, 1.13]), and cardiovascular mortality (HR 1.21 [1.09, 1.34]); however, sensitivity analyses suggested evidence of pleiotropy. The association of genetically-predicted TG with CAD persisted but its associations with mortality outcomes were attenuated towards the null after controlling for LDL-C.
Non-linear MR suggested the shapes of all these associations were monotonically increasing across the whole observed distribution of each lipid trait, with no diminution at low lipid levels. Such patterns were observed irrespective of sex or age.
Conclusions and relevance Our findings suggest that apoB (or equivalently LDL-C) increases CAD risk, all-cause mortality, and cardiovascular mortality all in a dose-dependent way. TG likely increases CAD risk, although the possible presence of pleiotropy is a limitation. These insights highlight the importance of LDL-C lowering for reducing cardiovascular morbidity and mortality across its whole distribution.
Question Do apolipoprotein B (apoB), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG) increase risk of coronary artery disease (CAD), all-cause mortality, or cause- specific mortality, and if so, what are the shapes of these relations?
Findings In this Mendelian randomization study including 347,797 European ancestry participants from UK Biobank, genetically-predicted apoB and LDL-C were positively associated with CAD, all- cause mortality, and cardiovascular mortality all in a dose-dependent way. Genetically-predicted TG was positively associated with CAD, although the presence of pleiotropy was suggested.
Meaning ApoB (or equivalently LDL-C) lowering reduces cardiovascular morbidity and mortality across its whole observed distribution.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
GY is supported by the Bau Tsu Zung Bau Kwan Yeu Hing Research and Clinical Fellowship from the University of Hong Kong. AMM is funded by the EU/EFPIA Innovative Medicines Initiative Joint Undertaking BigData@Heart grant 116074. SB is supported by the Wellcome Trust (225790/Z/22/Z) and the United Kingdom Research and Innovation Medical Research Council (MC_UU_00002/7). This research was supported by British Heart Foundation (RG/13/13/30194; RG/18/13/33946), BHF Cambridge CRE (RE/18/1/34212), and the National Institute for Health Research Cambridge Biomedical Research Centre (NIHR203312). The views expressed are those of the authors and not necessarily those of the National Institute for Health Research or the Department of Health and Social Care. The funders had no role in the study design, analyses, or interpretation of results. For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has been conducted using the UK Biobank Resource (Application number 98032). The UK Biobank obtained ethical approval from the North West Multi-centre Research Ethics Committee, and the participants provided written informed consent. The analysis of publicly available summary statistics does not require ethical approval.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
This study has been conducted using the UK Biobank Resource under Application number 98032. Summary-level data analyzed are available in the website http://www.nealelab.is/uk-biobank/ for UK Biobank (Neale lab), http://csg.sph.umich.edu/willer/public/glgc-lipids2021/ for GLGC, and https://www.ebi.ac.uk/gwas/ for GWAS of parental all-cause mortality.
